Cross-Sectional Surveys of Measles Antibodies in the Jiangsu Province of China from 2008 to 2010: The Effect of High Coverage with Two Doses of Measles Vaccine among Children

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Liu, Yuanbao ^a   Lu, Peishan ^a   Hu, Ying ^a   Wang, Zhiguo ^a   Deng, Xiuying ^a   Ma, Fubao ^a   Tao, Hong ^a   Jia, Chengmei ^a   Ding, Xiaoyan ^a   Yang, Haitao ^a   Liu, Pei ^b   Min, Jie ^b  

^a JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; MEASLES ANTIBODY; MEASLES VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANALYSIS OF VARIANCE; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CHILD; CHINA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; MAJOR CLINICAL STUDY; MALE; MEASLES; POPULATION RESEARCH; PRESCHOOL CHILD; SCHOOL CHILD; SEROPREVALENCE; SEX DIFFERENCE; TREND STUDY;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CHINA; CROSS-SECTIONAL STUDIES; DATA COLLECTION; FEMALE; GEOGRAPHY; HUMANS; INFANT; MALE; MEASLES VACCINE; MEASLES VIRUS; MIDDLE AGED; SEX DISTRIBUTION; VIRAL LOAD; YOUNG ADULT;

EID: 84879332199     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066771     Document Type: Article

References (31)

1. Chao M, Lixin H, Jing M, Yan Z, Lei C, et al. (2011) measles epidemiological characteristics and progress of measles elimintion in China, 2010. chinese Journal of vaccine and immunization 17: 4.
2. wenyuan Z (2001) Theory of Vaccines and Immunization. Shanghai: Shanghai scientific and technological literature publishing house. 370-384 p.
3. World Health Organization. Field guidelines for measles elimination. Available: http://www.wpro.who.int/publications/docs/FieldGuidelines_for_MeaslesElimination_0F24.pdf. Accessed 10 October 2012.
4. Fu C, Xu J, Liu W, Zhang W, Wang M, et al. (2010) Low measles seropositivity rate among children and young adults: A sero-epidemiological study in southern China in 2008. Vaccine 28: 8219-8223.
5. Liu YB, Tao H, Ma FB, Lu PS, Hu Y, et al. (2011) Sero-epidemiology of measles in general population in Jiangsu province of China: Application of mixture models to interpret the results from a cross-sectional study. Vaccine 29: 1000-1004.
6. Christenson B, Bottiger M, (1994) measles antibody- comparison of long-term vaccination titers, early vaccination titers and naturally acquired-immunity to and booster effects on the measles-virus. Vaccine 12: 129-133.
7. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, et al. (1990) measles antibody- reevaluation of protective titers. Journal of Infectious Diseases 162: 1036-1042.
8. R D, Core Team. (2009) R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. Available: http://www.R-project.org.Accessed 9 May 2012.
9. PAHO (2005) Measles Elimination Field Guide, Second Edition. Available: http://www.paho.org/english/ad/fch/im/fieldguide_measles.pdf.Accessed 11 June 2012.
10. Irons B, Dobbins JG, the Caribbean Vaccine Managers, (2011) The Caribbean Experience in Maintaining High Measles Vaccine Coverage. The Journal of Infectious Disease 204: S284-288.
11. Parker Fiebelkorn A, Redd SB, Gallagher K, Rota PA, Rota J, et al. (2010) Measles in the United States during the Postelimination Era. The Journal of Infectious Disease 202: 1520-1528.
12. Muscat M, Bang H, Wohlfahrt J, Glismann S, Mølbak K, (2009) Measles in Europe: an epidemiological assessment. The Lancet 373: 383-389.
13. Kim SS, Han HW, Go U, Chung HW, (2004) Sero-epidemiology of measles and mumps in Korea: impact of the catch-up campaign on measles immunity. Vaccine 23: 290-297.
14. Zhuo J, Geng W, Hoekstra EJ, Zhong G, Liang X, et al. (2011) Impact of Supplementary Immunization Activities in Measles-Endemic Areas: A Case Study From Guangxi, China. The Journal of Infectious Disease 204: S455-462.
15. Khetsuriani N, Deshevoi S, Goel A, Spika J, Martin R, et al. (2011) Supplementary Immunization Activities to Achieve Measles Elimination: Experience of the European Region. The Journal of Infectious Disease 204: S343-352.
16. Ki M, Choi BY, Oh JK, (2003) Measles vaccine effectiveness in elementary school student cohort, 1999-2001, South Korea. American Journal of Epidemiology 157: S48-S48.
17. Sniadack DH, Mendoza-Aldana J, Jee Y, Bayutas B, Lorenzo-Mariano KM, (2011) Progress and Challenges for Measles Elimination by 2012 in the Western Pacific Region. The Journal of Infectious Disease 204: S439-446.
18. Huiss S, Damien B, Schneider F, Muller CP, (1997) Characteristics of asymptomatic secondary immune responses to measles virus in late convalescent donors. Clinical and Experimental Immunology 109: 416-420.
19. Markowitz LE, Albrecht P, Orenstein WA, Lett SM, Pugliese TJ, et al. (1992) persistence of measles antibody after revaccination. Journal of Infectious Diseases 166: 205-208.
20. Vyse AJ, Gay NJ, Hesketh LM, Pebody R, Morgan-Capner P, et al. (2006) Interpreting serological surveys using mixture models: the seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century. Epidemiology and Infection 134: 1303-1312.
21. Jaber SM, (2006) A serological survey of measles, mumps and rubella immunity among school aged children in western Saudi Arabia. Saudi Medical Journal 27: 63-69.
22. Andrews N, Pebody RG, Berbers G, Blondeau C, Crovari P, et al. (2000) The European Sero-Epidemiology Network: standardizing the enzyme immunoassay results for measles, mumps and rubella. Epidemiology and Infection 125: 127-141.
23. Chen C-J, Lee P-I, Hsieh Y-C, Chen P-Y, Ho Y-H, et al. (2012) Waning population immunity to measles in Taiwan. Vaccine 30: 6721-6727.
24. De Serres G, Boulianne N, Defay F, Brousseau N, Benoit M, et al. (2012) Higher Risk of Measles When the First Dose of a 2-Dose Schedule of Measles Vaccine Is Given at 12-14 Months Versus 15 Months of Age. Clinical Infectious Diseases 55: 394-402.
25. WHO (2009) Measles Vaccine-WHO position paper. Weekly Epidemiological Record 84: 349-360.
26. Sudfeld CR, Navar AM, Halsey NA, (2010) Effectiveness of measles vaccination and vitamin A treatment. Int J Epidemiol 39: i48-55.
27. Yuanbao L, Hong T, Hongyu H, Peishan L, Ying H, et al. (2010) epidemiological charcteristics of adults measles and influence to elimination of measles in jiangsu province,2005-2008. Chinese Journal of vaccine and immunization 16: 307-309.
28. Sasaki A, Suzuki H, Sakai T, Sato M, Shobugawa Y, et al. (2007) Measles outbreaks in high schools closely associated with sporting events in Niigata, Japan. Journal of Infection 55: 179-183.
29. He H, Chen E-f, Li Q, Wang Z, Yan R, et al. (2013) Waning immunity to measles in young adults and booster effects of revaccination in secondary school students. Vaccine 31: 533-537.
30. Markowitz LE, Preblud SR, Fine PEM, Orenstein WA, (1990) duration of live measles vaccine-induced immunity. Pediatric Infectious Disease Journal 9: 101-110.
31. Bechini A, Boccalini S, Tiscione E, Pesavento G, Mannelli F, et al. (2012) Progress towards measles and rubella elimination in Tuscany, Italy: the role of population seroepidemiological profile. Eur J Public Health 22: 133-139.